BIOMAT Database Logo BIOMAT Database Logo

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. 2005

Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Department of Medicinal Chemistry, and Cancer Pharmacology, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA. Scott.VanderWel@pfizer.com

Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide an effective method for the treatment of proliferative diseases such as cancer. The pyrido[2,3-d]pyrimidin-7-one template has been identified previously as a privileged structure for the inhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representative examples. Obtaining selectivity for individual Cdk enzymes, particularly Cdk4, has been challenging. Here, we report that the introduction of a methyl substituent at the C-5 position of the pyrido[2,3-d]pyrimidin-7-one template is sufficient to confer excellent selectivity for Cdk4 vs other Cdks and representative tyrosine kinases. Further optimization led to the identification of highly potent and selective inhibitors of Cdk4 that exhibit potent antiproliferative activity against human tumor cells in vitro. The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer

Related Publications

Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
November 2000, Journal of medicinal chemistry,
Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents.
September 2003, Bioorganic & medicinal chemistry letters,
Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors.
February 2023, ACS medicinal chemistry letters,
Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors.
June 2016, European journal of medicinal chemistry,
Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.
October 2014, European journal of medicinal chemistry,
Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications.
November 2019, Molecules (Basel, Switzerland),
Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
May 2020, European journal of medicinal chemistry,
Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors.
May 2022, Bioorganic & medicinal chemistry letters,
Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors.
February 2024, Journal of medicinal chemistry,
Scott N VanderWel, and Patricia J Harvey, and Dennis J McNamara, and Joseph T Repine, and Paul R Keller, and John Quin, and R John Booth, and William L Elliott, and Ellen M Dobrusin, and David W Fry, and Peter L Toogood
Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
February 2021, European journal of medicinal chemistry,
Copied contents to your clipboard!